These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38226187)

  • 1. Long-term health care resource and cost savings with allergy immunotherapy: REACT study results.
    Fritzsching B; Porsbjerg C; Contoli M; Buchs S; Larsen JR; Freemantle N
    J Allergy Clin Immunol Glob; 2024 Feb; 3(1):100197. PubMed ID: 38226187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study.
    Contoli M; Porsbjerg C; Buchs S; Larsen JR; Freemantle N; Fritzsching B
    J Allergy Clin Immunol; 2023 Aug; 152(2):445-452.e4. PubMed ID: 36871918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study.
    Fritzsching B; Contoli M; Porsbjerg C; Buchs S; Larsen JR; Elliott L; Rodriguez MR; Freemantle N
    Lancet Reg Health Eur; 2022 Feb; 13():100275. PubMed ID: 34901915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis.
    Ellis AK; Mack DP; Gagnon R; Hammerby E; Gosain S
    Allergy Asthma Clin Immunol; 2023 Jan; 19(1):7. PubMed ID: 36653868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma.
    Vogelberg C; Brüggenjürgen B; Richter H; Jutel M
    Patient Prefer Adherence; 2020; 14():817-827. PubMed ID: 32494127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
    Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
    Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark.
    Rønborg S; Johnsen CR; Theilgaard S; Winther A; Hahn-Pedersen J; Andreasen JN; Olsen J
    J Med Econ; 2016 Aug; 19(8):735-41. PubMed ID: 26909663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunotherapy tablet: a cost-minimizing alternative in the treatment of tree pollen-induced seasonal allergic rhinitis in Canada.
    Ellis AK; Gagnon R; Hammerby E; Shen J; Gosain S
    Allergy Asthma Clin Immunol; 2021 Jul; 17(1):66. PubMed ID: 34238358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State of the Art: Development of a Sublingual Allergy Immunotherapy Tablet for Allergic Rhinitis in Japan.
    Ohashi-Doi K; Lund K; Mitobe Y; Okamiya K
    Biol Pharm Bull; 2020; 43(1):41-48. PubMed ID: 31902930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis.
    Devillier P; Wahn U; Zielen S; Heinrich J
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1199-1206. PubMed ID: 29072507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shifts in allergy practice in a COVID-19 world: Implications of pre-COVID-19 national health care provider and patient surveys of treatments for nasal allergies.
    Winders T; DuBuske L; Bukstein DA; Meltzer EO; Wallace D; Rance K
    Allergy Asthma Proc; 2021 Jul; 42(4):301-309. PubMed ID: 34030767
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of grass pollen allergen immunotherapy in adults.
    Di Bona D; Bilancia M; Albanesi M; Caiaffa MF; Macchia L
    Allergy; 2020 Sep; 75(9):2319-2329. PubMed ID: 32096242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma.
    Passalacqua G; Canonica GW; Bagnasco D
    Curr Allergy Asthma Rep; 2016 Nov; 16(12):88. PubMed ID: 27957697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis.
    Zielen S; Devillier P; Heinrich J; Richter H; Wahn U
    Allergy; 2018 Jan; 73(1):165-177. PubMed ID: 28561266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?
    Ellis AK; Gagnon R; Hammerby E; Lau A
    Allergy Asthma Clin Immunol; 2019; 15():27. PubMed ID: 31061666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient preferences for route of allergy immunotherapy: a comparison of four delivery methods.
    Chester JG; Bremberg MG; Reisacher WR
    Int Forum Allergy Rhinol; 2016 May; 6(5):454-9. PubMed ID: 26833457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preference for Immunotherapy with Tablets by People with Allergic Rhinitis.
    Tankersley M; Winders T; Aagren M; Brandi H; Hasse Pedersen M; Ledgaard Loftager AS; Bøgelund M
    Patient Prefer Adherence; 2021; 15():2539-2549. PubMed ID: 34819723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment.
    Manzotti G; Riario-Sforza GG; Dimatteo M; Scolari C; Makri E; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):224-227. PubMed ID: 27852426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: patients' experience with allergen immunotherapy.
    Skoner DP; Blaiss MS; Dykewicz MS; Smith N; Leatherman B; Bielory L; Walstein N; Craig TJ; Allen-Ramey F
    Allergy Asthma Proc; 2014; 35(3):219-26. PubMed ID: 24801464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.